Your session is about to expire
← Back to Search
Genetic Testing for Early-Stage Lung Cancer
Study Summary
This trial looks at whether genetic testing can help select the best treatment for patients with early-stage non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am suspected to have operable lung cancer that is not too advanced.I must register for the trial within a specific number of days after my surgery, depending on my treatment plan.I have a specific type of lung cancer that has been fully removed with no cancer left at the edges, and I have not received additional treatment if it's squamous cell carcinoma.You must have had surgery to remove non-small cell lung cancer with clear margins. If you have squamous cell carcinoma, you can only join if you haven't had additional treatment after surgery. Your cancer should be at specific stages, and you should be in good physical condition. You must be at least 18 years old and not have had certain treatments before. You can't have other advanced cancers or be pregnant or breastfeeding. If your genes have been tested locally, you can still join the study.
- Group 1: A081105 Arm C (unblinded erlotinib hydrochloride)
- Group 2: A081801 Arm A (platinum doublet, observation)
- Group 3: A081801 Arm C (platinum doublet, combination pembrolizumab)
- Group 4: EA5142 Arm I (nivolumab)
- Group 5: A081105 Arm B (placebo)
- Group 6: E4512 Arm B (observation)
- Group 7: EA5142 Arm II (observation)
- Group 8: E4512 Arm A (crizotinib)
- Group 9: A081801 Arm B (platinum doublet, sequential pembrolizumab)
- Group 10: A081105 Arm D (observation)
- Group 11: A081105 Arm A (blinded erlotinib hydrochloride)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the clinical trial accepting at this time?
"That is accurate. As per data hosted on clinicaltrials.gov, this medical trial was first posted on August 18th 2014 and it is still actively recruiting patients; the study aims to enrol 8300 participants from 100 different sites."
Are there opportunities for enrolment in this experiment yet?
"Affirmative, clinicaltrials.gov indicates that this research is actively enrolling participants. It was first advertised on August 18th 2014 and the most recent update came December 1st 2022. The goal of this trial is to recruit 8300 patients from 100 different sites."
What diseases does Pembrolizumab usually prove efficacious for?
"Pembrozulimab is often employed to treat malignant melanoma of the skin, metastatic hepatocellular carcinoma and neoplasm metastasis."
In what areas are the trials of this experiment being conducted?
"This trial is primarily based at Aurora Health Care Germantown Health Center in Wisconsin, Aurora Cancer Care-Grafton in Minnesota and Marshfield Medical Center-River Region in Iowa. An additional 100 sites are also participating across the country."
Can you provide a catalogue of experiments utilizing Pembrolizumab?
"Originally studied at the City of Hope Comprehensive Cancer Center in 1997, pembrolizumab has now been explored through 3729 completed studies. Currently, 3179 active trials are being conducted with a substantial amount of this research taking place in Germantown, Wisconsin."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger